ライフサイエンスコーパス: splenomegaly

1 mice exhibited hemophagocytosis, anemia, and splenomegaly.

2 consequent extramedullary hematopoiesis and splenomegaly.

3 terized by thrombocytosis, neutrophilia, and splenomegaly.

4 icantly higher hemoglobin levels and reduced splenomegaly.

5 s (group B) progressed, of whom 15 developed splenomegaly.

6 echogenicity on ultrasonography, and 65% had splenomegaly.

7 less than or equal to 174,000 per mm(3) and splenomegaly.

8 ditionally presented anemia, leukopenia, and splenomegaly.

9 f the Hopx(-/-) mice developed cytopenia and splenomegaly.

10 ultrasound imaging showed the development of splenomegaly.

11 n leukemia cell counts, lymphadenopathy, and splenomegaly.

12 xtramedullary hematopoiesis in the liver and splenomegaly.

13 ] > 100 x 10(9)/L), as well as resolution of splenomegaly.

14 ation of RA characterized by neutropenia and splenomegaly.

15 e models showed dermatitis, blepharitis, and splenomegaly.

16 eticulocytosis, erythropoietin abundance and splenomegaly.

17 with a bleeding tendency, myelofibrosis, and splenomegaly.

18 sponse rates were 30% for anemia and 42% for splenomegaly.

19 matic increase in splenic megakaryocytes and splenomegaly.

20 ative disease (LPD) that results in dramatic splenomegaly.

21 ating their infection and resulting in acute splenomegaly.

22 6 release, extramedullary hematopoiesis, and splenomegaly.

23 ultimately results in cytopenias and massive splenomegaly.

24 17 population in the spleen, and ameliorated splenomegaly.

25 hite blood cells, associated with increasing splenomegaly.

26 llary hematopoiesis (myeloid metaplasia) and splenomegaly.

27 varices or ascites or low platelet count and splenomegaly.

28 such as hypoalbuminemia, bilirubinemia, and splenomegaly.

29 ty to trigger massive lymphoid expansion and splenomegaly; 2) the proportion of Th1 cells among infil

30 ing two of the following: (1) hepatomegaly+/-splenomegaly; (2)>6 months elevation of ALT (>1.5x upper

31 ake value [SUVmax], 6.0; range, 2.0-8.0) and splenomegaly (3.4; 1.2-11.0), with increased metabolism

32 vated interleukin 6 (57/63), hepatomegaly or splenomegaly (52/67), fever (33/64), oedema, ascites, an

33 s (100%), peripheral lymphadenopathy (100%), splenomegaly (72%), hepatomegaly (50%), and edema (28%).

34 Splenomegaly, a characteristic feature of E. muris infec

35 urrently, Cdc42 deficiency caused anemia and splenomegaly accompanied with decreased bone marrow eryt

36 We describe a patient who had fever and splenomegaly after traveling to Peru and also had bacter

37 mice exhibited reduced bacterial burden and splenomegaly, along with distinct effector T-cell and mo

38 at C. burnetii infection induced more-severe splenomegaly and a higher bacterial burden in the spleen

39 developed a myelofibrosis associated with a splenomegaly and a marked osteosclerosis.

40 ls develop a myeloproliferative disease with splenomegaly and aberrant myelopoiesis.

41 demonstrate that anti-CD47 (MIAP410) causes splenomegaly and activation of DCs and T cells, without

42 t the mutated kinase indicate a reduction in splenomegaly and alleviation of night sweats, fatigue, a

43 expatriate patient who presented with acute splenomegaly and anemia 3 years after visiting Ecuador.

44 ed response to TLR9 agonism, including worse splenomegaly and anemia.

45 deficiencies were not equivalent in terms of splenomegaly and bacterial clearance.

46 17F(+) MPN, oral INCB018424 markedly reduced splenomegaly and circulating levels of inflammatory cyto

47 oreductive drugs such as hydroxyurea for the splenomegaly and constitutional symptoms, and splenectom

48 is the current best available therapy for MF splenomegaly and constitutional symptoms.

49 ciated with marked and durable reductions in splenomegaly and disease-related symptoms, improvements

50 llenged BCG-immune mice developed a striking splenomegaly and elevated CD4 and CD8 T-cell responses b

51 hus, 4- to 6-week-old IRP1(-/-) mice exhibit splenomegaly and extramedullary hematopoiesis, which is

52 which heterozygous animals are anaemic with splenomegaly and extramedullary hematopoiesis.

53 A 14-year-old boy presented with splenomegaly and hemolysis.

54 d of malaria is increased by the presence of splenomegaly and hepatomegaly but individual findings ar

55 showed a delayed onset of leukemia, reduced splenomegaly and hepatomegaly, and a longer survival tha

56 splay a lupus-like autoimmune phenotype with splenomegaly and high autoantibodies titers.

57 meaningful benefits, particularly decreased splenomegaly and improvement in constitutional symptoms,

58 ost-ET MF achieved significant reductions in splenomegaly and improvements in symptoms with ruxolitin

59 alleviating the symptomatic burden, reducing splenomegaly and improving quality of life in patients w

60 phase 3 studies to be effective in reducing splenomegaly and improving symptoms in myelofibrosis pat

61 o3 causes a myeloproliferative syndrome with splenomegaly and increased hematopoietic progenitors (HP

62 nses in C9orf72(-/-) immune cells as well as splenomegaly and inflammation in C9orf72(-/-) mice.

63 eletion using MxCre or Scl-CreER(T) leads to splenomegaly and leukemia formation, which occurs after

64 proliferation, extramedullary hematopoiesis, splenomegaly and leukemic progression.

65 od and, at 6 months of age, exhibited marked splenomegaly and leukophilia.

66 ead, C9orf72 null mice developed progressive splenomegaly and lymphadenopathy with accumulation of en

67 nt lyn(-/-)IL-10(-/-) mice manifested severe splenomegaly and lymphadenopathy, dramatically increased

68 efore disease initiation resulted in reduced splenomegaly and lymphadenopathy, impaired expansion and

69 increased T-independent antibody responses, splenomegaly and lymphadenopathy.

70 Map3k7(DeltaM/DeltaM)) led to development of splenomegaly and lymphomegaly associated with neutrophil

71 or that has demonstrated rapid reductions in splenomegaly and marked improvement in disease-related s

72 asing the burden of symptoms associated with splenomegaly and MF-related constitutional symptoms, it

73 d for at least 5 weeks, displaying increased splenomegaly and more severe splenitis than infected mic

74 while surviving mice had even more prominent splenomegaly and normal-appearing lungs.

75 ration of minihepcidin significantly reduces splenomegaly and normalizes hematocrit levels.

76 Female Prkca(-/-) mice develop splenomegaly and reduced marrow GBA1 expression reminisc

77 or activity to gossypol in terms of reducing splenomegaly and reducing B-cell counts in spleens of Bc

78 247), which, contrastingly, produced greater splenomegaly and reticulocytosis.

79 Finally, we observed a decrease in splenomegaly and serum and liver iron in anti-ERFE-treat

80 Mfsd1 knockout mice develop splenomegaly and severe liver disease.

81 d significantly reduces Nras(G12D/+)-induced splenomegaly and spontaneous colony formation and prolon

82 We observed severe splenomegaly and structural destruction in the spleen wi

83 e I (NMI), SCID mice developed pneumonia and splenomegaly and succumbed to infection, whereas wild-ty

84 Fedratinib therapy significantly reduced splenomegaly and symptom burden in patients with MF.

85 The splenomegaly and symptom reductions achieved with ruxoli

86 xolitinib produced significant reductions in splenomegaly and symptomatic burden and improved surviva

87 cular those with myelofibrosis and extensive splenomegaly and symptomatic burden, after the introduct

88 apy at controlling haematocrit and improving splenomegaly and symptoms in patients with polycythaemia

89 fter the operation portal hypertension, with splenomegaly and symptoms of the liver cirrhosis occurre

90 We found that responses in splenomegaly and symptoms, as well as the risk of develo

91 K2 inhibitor therapy improves MPN-associated splenomegaly and systemic symptoms but does not signific

92 ough clinically tested JAK inhibitors reduce splenomegaly and systemic symptoms, molecular responses

93 otective immunity that significantly reduces splenomegaly and the bacterial burden in spleen and lung

94 Splenomegaly and the increased neoplastic stem cell pool

95 MHV68 lytic replication, including increased splenomegaly and the presence of infectious virus in the

96 All patients had baseline splenomegaly and thrombocytopenia (mostly moderate or se

97 orrected immunological abnormalities such as splenomegaly and thymic atrophy in Apc(Min/+) mice.

98 range, reduced reticulocytosis, reversal of splenomegaly and up to 7% beta-globin gene correction in

99 , mice infected with FMLV-IL-1beta exhibited splenomegaly and viral loads 300-fold higher than those

100 h male and female IL-3 KO mice had increased splenomegaly and were more anemic than corresponding WT

101 USP21-deficient mice spontaneously developed splenomegaly and were more resistant to VSV infection wi

102 hematopoietic cells developed virus-induced splenomegaly and were more resistant to VSV infection.

103 t for foxp3a displayed excess T lymphocytes, splenomegaly, and a profound inflammatory phenotype that

104 lary hematopoiesis, circulating CD34+ cells, splenomegaly, and a propensity to evolve to acute myeloi

105 ation of ineffective erythropoiesis (IE) and splenomegaly, and an increase in total hemoglobin levels

106 , reversal of ineffective erythropoiesis and splenomegaly, and an increase in total hemoglobin levels

107 racterized by myeloid-dominant leukocytosis, splenomegaly, and an increase of hematopoietic stem/prog

108 ical manifestations include lymphadenopathy, splenomegaly, and autoimmune cytopenias.

109 ome of chronic nonmalignant lymphadenopathy, splenomegaly, and autoimmunity associated with a mutatio

110 oms, the absence of platelet alpha-granules, splenomegaly, and bone marrow (BM) fibrosis.

111 omplications of IE, including iron overload, splenomegaly, and bone pathology, while reducing erythro

112 cued chronic activation of conventional DCs, splenomegaly, and colitis.

113 manifestations, including pancreatic cysts, splenomegaly, and common bile duct dilation.

114 a myeloid malignancy associated with anemia, splenomegaly, and constitutional symptoms.

115 blast cells in the peripheral blood, reduced splenomegaly, and corrected a pathologically low myeloid

116 Decreased body temperature, weight loss, splenomegaly, and deformation of the tails were observed

117 deficiency (hypogammaglobulinemia [low IgA], splenomegaly, and diminished immunization responses).

118 megakaryocyte emperipolesis of neutrophils, splenomegaly, and elevated serum vitamin B12 levels.

119 autoantibodies, reduced lymphadenopathy and splenomegaly, and extended survival.

120 sia in the bone marrow and spleen, displayed splenomegaly, and had reduced levels of plasma erythropo

121 ever, otitis media, pneumonia, hepatomegaly, splenomegaly, and hospitalization in HIV-infected infant

122 years) with polycythaemia vera, no palpable splenomegaly, and hydroxyurea resistance or intolerance

123 including leukocytosis, reduced hematocrit, splenomegaly, and increased bone marrow reticulin.

124 emia and reduces ineffective erythropoiesis, splenomegaly, and iron loading.

125 st completely abrogates cellular expansions, splenomegaly, and liver inflammation associated with ant

126 acterized by dermatitis, liver inflammation, splenomegaly, and loss of Peyer's patches.

127 ized by cytopenias, constitutional symptoms, splenomegaly, and marrow histopathological abnormalities

128 bited reduced thrombocythemia, neutrophilia, splenomegaly, and neoplastic stem cell pool.

129 rder characterized by macrothrombocytopenia, splenomegaly, and paucity of alpha-granules in megakaryo

130 on in mice leads to multiorgan inflammation, splenomegaly, and premature death.

131 IL-33trap inhibits eosinophil infiltration, splenomegaly, and production of signature cytokines in s

132 characterized by leukocytosis, monocytosis, splenomegaly, and progressive anemia.

133 hil CD18 silencing resulted in neutrophilia, splenomegaly, and significant defects in neutrophil traf

134 0 decreases leukemic allelic burden, reduces splenomegaly, and significantly increases survival of Ja

135 frequency of thromboembolic events, palpable splenomegaly, and splenectomy; chemotherapy exposure; le

136 by ineffective erythropoiesis (IE), anemia, splenomegaly, and systemic iron overload.

137 hal phenotype characterized by pancytopenia, splenomegaly, and the accumulation of monocytoid cells.

138 kopenia, higher blast count, symptoms, large splenomegaly, and unfavorable karyotype.

139 rombocytopenia; HGF, MIG, IL-1RA, and marked splenomegaly; and IL-1RA, IL-2R, IP-10, MIP-1beta, and J

140 is involved in inhibiting the development of splenomegaly, anemia, and erythropoiesis.

141 es), strong progenitor and LKS mobilization, splenomegaly, anemia, and loss of lymphoid lineages.

142 pleural effusion, ascites, hepatomegaly, and splenomegaly are highly suggestive of dengue fever in cl

143 Reductions in lymphadenopathy and splenomegaly are seen within weeks and are frequently ac

144 Interestingly, EPCR(R84A/R84A) mice develop splenomegaly as a result of bone marrow (BM) failure.

145 nternational Normal Ratio levels were lower, splenomegaly, ascites, and cirrhosis were more common (a

146 ldhood with nonmalignant lymphadenopathy and splenomegaly associated with a characteristic expansion

147 is results in chronic lymphadenopathy and/or splenomegaly associated with autoimmune phenomena.

148 The Irf5(-/-) mice develop an age-related splenomegaly, associated with a dramatic accumulation of

149 These symptoms were preceded by splenomegaly at an early age, which was associated with

150 who presented with chronic lymphadenopathy, splenomegaly, autoantibodies, elevated immunoglobulins a

151 normalities characteristic of SLE, including splenomegaly, autoantibody production, frequencies of ma

152 inactive mutants of IRAK1 or IRAK4 prevented splenomegaly, autoimmunity, and liver and kidney inflamm

153 umococcal infection can, under conditions of splenomegaly, be readily compensated for by activated re

154 ontributing to extramedullary hematopoiesis, splenomegaly, BM failure, and decreased levels of circul

155 hibitors improve constitutional symptoms and splenomegaly but do not significantly reduce mutant alle

156 lutary effect on constitutional symptoms and splenomegaly but have yet to produce histopathologic or

157 mice exhibited marked reductions in AEAs and splenomegaly but not in anti-nuclear Abs.

158 one or with fusion vaccine induced transient splenomegaly but without apparent toxicity.

159 nias, occurrence of autoimmune diseases, and splenomegaly, but was undetectable in control cases with

160 s proven to be effective in improving IE and splenomegaly by inducing iron restriction.

161 Splenectomy for massive splenomegaly can be performed safely and offers durable

162 d a more complete spectrum of HLH, including splenomegaly, coagulopathy, and decreased NK cell cytoto

163 It is notably characterized by splenomegaly, complex skeletal involvement, ischemic eve

164 myeloproliferative neoplasm characterised by splenomegaly, cytopenias, bone marrow fibrosis, and debi

165 litating disease manifestations (eg, massive splenomegaly, cytopenias, constitutional symptoms, and t

166 liferative neoplasm characterized by anemia, splenomegaly, debilitating constitutional symptoms, and

167 ematocrit, white blood cells, platelets, and splenomegaly, deletion of Stat5 in the Jak2V617F knockin

168 The study found that thrombocytopenia, splenomegaly, didanosine use, elevated aminotransferases

169 rast to residual lymphadenopathy, persisting splenomegaly does not impact outcome in patients with MR

170 These changes were accompanied by splenomegaly due to lymphoid hyperplasia and increased h

171 ound that systemic infection induced anemia, splenomegaly, elevated erythropoietin (EPO) levels, and

172 typical clinical features of HLH, including splenomegaly, elevated serum IFNgamma, and anemia.

173 provoke disease, while its absence produced splenomegaly, enlarged lymph nodes, and mild social inte

174 ozygous FOG-1(R3K5A) mice were found to have splenomegaly, extramedullary erythropoiesis, granulocyto

175 pendent autoimmune manifestations, including splenomegaly, extramedullary hematopoiesis, and autoanti

176 These mice develop severe neutrophilia, splenomegaly, extramedullary hematopoiesis, decreased bo

177 patients presented with lymphadenopathy and splenomegaly; fever, hepatitis, and pancytopenia were co

178 The phenotype included splenomegaly, fibrotic and hypercellular bone marrow, ex

179 Enteropathy, autoimmunity, granulomas, and splenomegaly formed a set of interrelated features, wher

180 characterized with a female predominance, a splenomegaly, gain of chromosome 3, and CD27 expression.

181 lytic anemia, or neutropenia, in addition to splenomegaly, generalized or worrisome lymphadenopathy,

182 Other main inclusion criteria were palpable splenomegaly (>/=5 cm below the left costal margin), Eas

183 Splenectomy for massive splenomegaly (>1500 g) provides palliation but is associ

184 isease was observed until platelet count and splenomegaly had improved.

185 MRD-negative PR who presented with residual splenomegaly had only a similar PFS (63 months) compared

186 Patients with >/= 50% reduction in splenomegaly had significantly prolonged survival versus

187 BB agonists given to unimmunized mice induce splenomegaly, hepatitis, and other immune system anomali

188 The Id3(-/-) mice with lymphoma showed splenomegaly, hepatomegaly, and lymphadenopathy with inv

189 mia: leukocytosis with maturing neutrophils, splenomegaly, hepatomegaly, and myeloid infiltration int

190 a associated pathological changes, including splenomegaly, hepatomegaly, or granulomatous disease.

191 cells began to hyperproliferate and induced splenomegaly; however, isotype switching and autoantibod

192 cted B6.PD-1(-/-) mice developed more severe splenomegaly, hypergammaglobulinemia, and immunodeficien

193 LE)-like disease that included leukocytosis, splenomegaly, hypergammaglobulinemia, antinuclear autoan

194 the murine retroviral isolate LP-BM5 induces splenomegaly, hypergammaglobulinemia, profound B- and T-

195 haracterized by early-onset lymphadenopathy, splenomegaly, immune cytopenias, and an increased risk f

196 Hepatomegaly was found in 34% and splenomegaly in 56% of patients.

197 ele (CRTC2/3m mice) develop neutrophilia and splenomegaly in adulthood due to the up-regulation of gr

198 respectively, exacerbated or did not improve splenomegaly in beta-thalassemic mice.

199 y, these results reveal that the age-related splenomegaly in Irf5(-/-) mice is associated with an acc

200 peripheral blood counts and markedly reduced splenomegaly in Jak2V617F knock-in mice compared with pl

201 ortant role in the management of symptomatic splenomegaly in MF patients.

202 The safety was revealed by the absence of splenomegaly in mice that were inoculated with the mutan

203 monella infection commonly induces prolonged splenomegaly in murine or human hosts.

204 for treatment of constitutional symptoms and splenomegaly in myelofibrosis, but the effect of these a

205 igher in VAD pigs in spleen (coincident with splenomegaly in other VAD animals) prechallenge and inte

206 exception of a higher prevalence of palpable splenomegaly in patients with fibrosis (P < .01).

207 electively improves liver pathology, but not splenomegaly in the mice.

208 therapeutic algorithm of RA, neutropenia and splenomegaly in the spectrum of LGL leukemia and Felty's

209 vo) significantly decreased tumor weight and splenomegaly in tumor-bearing mice with reduced accumula

210 ed to increased WBC counts, monocytosis, and splenomegaly in WT recipient mice.

211 assigned phlebotomy-dependent patients with splenomegaly, in a 1:1 ratio, to receive ruxolitinib (11

212 ciated with increasing portal vein diameter, splenomegaly, increased serum immunoglobulin G level, an

213 In a murine model of the splenomegaly-inducing retrovirus Friend virus complex (F

214 d survival and reduced serum autoantibodies, splenomegaly, intrarenal leukocyte trafficking, and end

215 reduced white blood cell count, blast cells, splenomegaly, lactate dehydrogenase levels, and bone pai

216 apid objective response (>/=50% reduction of splenomegaly) lasting for 12 months or more, and this th

217 myeloproliferative disease, characterized by splenomegaly, leukocytosis, and myeloid hypercellularity

218 kly administration of the naked mAbs reduced splenomegaly, liver tumor spots, and tumor burden in BLC

219 ed infants with P/EP CMV, symptoms including splenomegaly, lymphadenopathy, and hepatomegaly were ass

220 including loss of marginal zone macrophages, splenomegaly, lymphadenopathy, autoantibodies (including

221 its measures of B-cell hyperactivity such as splenomegaly, lymphadenopathy, elevated serum IL-6, elev

222 These included splenomegaly, lymphadenopathy, hepatomegaly, multifocal

223 eport here that Rabgef1-/- mice also develop splenomegaly, lymphadenopathy, myeloid hyperplasia, and

224 layed a dramatic phenotype, characterized by splenomegaly, lymphadenopathy, thymic atrophy, and multi

225 with CEP-33779 extended survival and reduced splenomegaly/lymphomegaly.

226 As in GPS, Nbeal2(-/-) mice exhibit splenomegaly, macrothrombocytopenia, and a deficiency of

227 Future care of MF patients, including splenomegaly management, will continue to require the he

228 duction was dependent on three subloci, with splenomegaly mapping to two of the subloci and expansion

229 ological syndrome akin to typhoid fever with splenomegaly, microcytic anemia, extramedullary erythrop

230 e changes were accompanied by a reduction in splenomegaly, more organized T and B cell zones, and an

231 oked a clonal myelomonocytic cell expansion, splenomegaly, multi-organ infiltration, genomic instabil

232 res of human plasma cell-type MCD, including splenomegaly, multifocal lymphadenopathy, hypergammaglob

233 and childhood onset chronic lymphadenopathy, splenomegaly, multilineage cytopenias, and an increased

234 deletion of Pten in mice lacking G-CSF, the splenomegaly, myeloproliferative disease, and splenic HS

235 and laboratory manifestations include fever, splenomegaly, neurologic dysfunction, coagulopathy, live

236 ind spontaneous MPD that is characterized by splenomegaly, neutrophilia, and extramedullary hematopoi

237 optive transfer of CRTC2/3m BM conferred the splenomegaly/neutrophilia phenotype in WT recipients.

238 The reduced splenomegaly observed following infection with SL1344 tr

239 roved erythroid differentiation, and reduced splenomegaly of iron-deficient Hri(-/-) and eAA mice.

240 therapeutic dose of anti-GITR did not induce splenomegaly or increase serum alanine transaminase.

241 s, or any combination of these together with splenomegaly or myelofibrosis, and it can take years for

242 botomy) with complete resolution of palpable splenomegaly or symptoms in the absence of a thrombotic

243 achieved before the patients develop massive splenomegaly or undergo splenectomy.

244 o significant difference in lymphadenopathy, splenomegaly, or anti-chromatin autoantibody titer betwe

245 or axillary adenopathy, palatine petechiae, splenomegaly, or atypical lymphocytosis is associated wi

246 erial or venous thrombosis, marrow fibrosis, splenomegaly, or transformation to acute leukemia, albei

247 e developed gastric hyperplasia (P < .0001), splenomegaly (P < .0001), and increased serum antibody t

248 tations (P = .015), deletion 13q (P = .006), splenomegaly (P = .02), and thrombocytopenia (P = .004),

249 abnormal liver echogenicity (P < 0.001); and splenomegaly (P = 0.001) at ultrasound.

250 ore portosystemic collaterals (P = 0.01) and splenomegaly (P = 0.01) on ultrasound, and lower platele

251 09 to July 2012 among eligible patients with splenomegaly plus thrombocytopenia and/or anemia.

252 erative neoplasm associated with cytopenias, splenomegaly, poor quality of life, and shortened surviv

253 Eligible patients had clinical splenomegaly poorly controlled with standard therapies o

254 red with that of a normal control), ascites, splenomegaly, portal hypertension (portal vein velocity,

255 d blood cells, leukocytosis, thrombocytosis, splenomegaly, reduced serum erythropoietin (Epo) levels

256 In particular, management of symptomatic splenomegaly remains one of the most perplexing aspects

257 expansion of leukocytes, the actual cause of splenomegaly remains unclear.

258 tive mononuclear cells causing hepatomegaly, splenomegaly, severe anemia, and death.

259 taIEC) mice had low-grade inflammation (mild splenomegaly, shortened colons, and increased fecal leve

260 .95; positive LR, 5.3 [95% CI, 2.1-13]), and splenomegaly (specificity range, 0.71-0.99; positive LR

261 Splenomegaly started early in life; 60% of children youn

262 r disease symptoms such as IC generation and splenomegaly, suggesting that GN and other inflammatory

263 f limited diagnostic utility but presence of splenomegaly (summary likelihood ratio [LR], 3.3; 95% co

264 resence of fever (LR, 5.1; 95% CI, 4.9-5.3), splenomegaly (summary LR, 6.5; 95% CI, 3.9-11.0), hyperb

265 n shortening, colon histological damage, and splenomegaly than did wild-type (WT) mice.

266 arginal zone macrophages associated with the splenomegaly that follows a variety of viral and protozo

267 y, including anti-nuclear autoantibodies and splenomegaly, that are not found in Unc93b1(3d/3d) DKO m

268 a-subunit of the type 1 IFNR did not prevent splenomegaly, the appearance of high serum levels of aut

269 th receptor function causes lymphadenomegaly/splenomegaly, the expansion of T-cell receptor alphabeta

270 e rheumatoid arthritis (RA), neutropenia and splenomegaly, thereby resembling the manifestations obse

271 e to A. phagocytophilum infection and showed splenomegaly, thrombocytopenia, and monocytopenia.

272 in mice revealed Hippo kinase loss to induce splenomegaly, thrombocytopenia, megakaryocytic dysplasia

273 linked to survival, glomerulonephritis, and splenomegaly, to investigate its role in AIHA.

274 ice exhibited marked facial edema and marked splenomegaly upon gross examination, while the intraderm

275 WT mice, RdRP mice had significantly reduced splenomegaly, viral loads, and infection of multiple tar

276 diet animal model, a significant increase in splenomegaly was observed, but no significant change in

277 Splenectomy for massive splenomegaly was performed most commonly for non-Hodgkin

278 t from New Caledonia presenting with febrile splenomegaly,weight loss, life-threatening autoimmune ha

279 Ascites and splenomegaly were independent predictors for the presenc

280 ative MRI relaxation times as well as severe splenomegaly were observed in the heart, liver and splee

281 Lymphadenopathy and splenomegaly, which are characteristic traits of the MRL

282 ion, spontaneous intestinal inflammation and splenomegaly, which can be rescued by antibiotic treatme

283 riction (by targeting Tmprss6) would improve splenomegaly while preserving the beneficial effects on

284 in patients with polycythaemia vera without splenomegaly who need second-line therapy.

285 oms in patients with polycythaemia vera with splenomegaly who were inadequately controlled with hydro

286 Tumor progression induced splenomegaly with a dramatic increase (22.1%) in CD11b(+

287 major reduction of bone marrow IgD(+) cells, splenomegaly with a loss of white pulp and grossly expan

288 At this stage mice exhibited severe splenomegaly with abnormal B-cell-derived white pulp exp

289 ted growth retardation, premature death, and splenomegaly with altered architecture and extramedullar

290 ficient CAR T cells reexpanded, resulting in splenomegaly with disruption of normal splenic architect

291 erized by elevated erythropoietin levels and splenomegaly with excess erythropoiesis.

292 We report that W(sh) animals exhibit splenomegaly with expanded myeloid and megakaryocyte pop

293 blood cells, hypercellular bone marrow (BM), splenomegaly with extramedullary erythropoiesis and eryt

294 Ultrasound demonstrated hepato-splenomegaly with multiple granulomas as well as ascites

295 utropenia, bone marrow hypercellularity, and splenomegaly with myeloid infiltration.

296 ction in SCD/NRF2(-/-) mice produced greater splenomegaly with red pulp expansion and obscured archit

297 Nix null mice exhibited massive splenomegaly, with splenic and bone marrow erythroblasto

298 in autoimmune disease, lymphadenopathy, and splenomegaly within 1 to 3 months of starting sirolimus.

299 ations is the simplest approach for reducing splenomegaly, yet achieving symptomatic response without

300 esults in a rapid reduction of the degree of splenomegaly, yet the mechanism underlying this effect r